PORTLAND, Ore., Oct. 3 /PRNewswire-FirstCall/ -- Bioject Medical Technologies Inc. , a leading developer of needle-free drug delivery systems, announced today that it has received a Phase II Small Business Innovation Research contract from the Centers for Disease Control and Prevention ("CDC") for further development of a Disposable Cartridge Jet Injection device (DCJI) for safer, needle-free global immunizations.
In 2005, the Company received Phase I funding for the initial prototype system. In Phase I, the Company designed and built a spring-powered prototype and proved its performance for intramuscular, subcutaneous and intradermal injections. The Phase II funding is for a two-year period and is for improvements in product design and the continued development of the device and its unique single use auto-disable cartridge.
"We are pleased to have received the Phase II contract from the CDC for the development of our immunization device with needle-free auto-disable cartridges," said Jim O'Shea, Chairman, President and CEO of Bioject. "This funding will allow us to continue to develop this new needle-free system, targeting the growing immunization market in developed and developing countries."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information about Bioject, visit www.bioject.com .
Bioject Medical Technologies Inc.CONTACT: Jim O'Shea, Chief Executive Officer, +1-503-692-8001, ext. 4161,or Chris Farrell, Vice President of Finance, +1-503-692-8001, ext. 4132,both of Bioject Medical Technologies Inc.
Web site: http://www.bioject.com//
